Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.20264 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization and Antimicrobial Efficacy of a Bacteriophage Targeting Multidrug-Resistant .
ACS Infect Dis
September 2025
Animal-Derived Food Safety Innovation Team, College of Veterinary Medicine, Anhui Agricultural University, Hefei 230036, China.
The emergence of multidrug-resistant (MDR) poses a significant threat to global public health, necessitating alternative therapeutic strategies. In this study, we isolated and characterized a novel lytic bacteriophage (phage), vB_EcoM_51, from poultry farm sewage and evaluated its potential against MDR . Transmission electron microscopy revealed that the phage exhibits morphological features typical of the family, including a polyhedral head (∼66.
View Article and Find Full Text PDFFrom clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem?
Curr Opin Infect Dis
September 2025
Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Purpose Of Review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. This review summarizes current knowledge on the optimal use of SUL-DUR, whether administered alone or in combination with carbapenems, particularly imipenem.
Recent Findings: Data from registrational trial demonstrate that SUL-DUR is an effective and well tolerated treatment option for CRAB severe infections.
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFSafety and efficacy of remimazolam combined with alfentanil in flexible fiberoptic bronchoscopy: A randomized controlled trial.
J Int Med Res
September 2025
Department of Anesthesiology, Lishui People's Hospital, China.
ObjectiveThe sedation protocol for flexible fiberoptic bronchoscopy has long been a matter of inconclusiveness. The aim of this study was to evaluate the safety and efficacy of remimazolam combined with alfentanil in flexible fiberoptic bronchoscopy and provide insights for optimizing clinical anesthesia strategies.MethodsThis study was a randomized, single-blind controlled trial.
View Article and Find Full Text PDFFractional CO2 Versus Radiofrequency as Hair Regrowth Enhancers for Female Androgenic Alopecia: A Randomized Controlled Trial.
Dermatol Surg
September 2025
All authors are affiliated with the Department of Dermatology, Kasr Al Ainy Teaching Hospital, Cairo University, Cairo, Egypt.
Background: Androgenic alopecia (AGA) is a cosmetically disfiguring condition, which accounts for most cases of diffuse hair loss among females, negatively impacting their quality of life. Combining Fractional CO2 (FCO2) or Fractional Microneedling Radiofrequency (FMRF) with topical minoxidil 5% could achieve a better clinical outcome.
Objective: To compare efficacy and safety of FCO2 and FMRF, combined with minoxidil, for the treatment of female AGA.